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ABSTRACT
Hereditary gelsolin amyloidosis (AGel amyloidosis) is an autosomal dominant
form of systemic amyloidosis caused by a c.640G>A or c.640G>T mutation in
the gene coding for gelsolin. Principal clinical manifestations include corneal lattice
dystrophy, cranial neuropathy and cutis laxa with vascular fragility. Signs of minor
CNS involvement have also been observed, possibly related to cerebral amyloid
angiopathy (CAA). To investigate further if AGel amyloidosis carries a risk for a
specific neuropsychological or psychiatric symptomatology we studied 35 AGel
patients and 29 control subjects. Neuropsychological tests showed abnormalities in
visuocontructional and -spatial performance in AGel patients, also some indication
of problems in processing efficacy was found. At psychiatric evaluation the patient
group showed more psychiatric symptomatology, mainly depression. In brain MRI,
available in 16 patients and 14 controls, we found microhemorrhages or microcal-
cifications only in the patient group, although the number of findings was small.
Our study shows that AGel amyloidosis can be associated with visuoconstructional
problems and depression, but severe neuropsychiatric involvement is not character-
istic. The gelsolin mutation may even induce cerebrovascular fragility, but further
epidemiological and histopathological as well as longitudinal follow-up studies are
needed to clarify gelsolin-related vascular pathology and its clinical consequences.
Subjects Cognitive Disorders, Neurology, Psychiatry and Psychology,
Radiology and Medical Imaging
Keywords Hereditary amyloidosis, Gelsolin amyloidosis, Neuropsychological testing,
Visuoconstructional problems, Depression, Magnetic resonance imaging
INTRODUCTION
Hereditary gelsolin amyloidosis (AGel amyloidosis) is an autosomal dominant form of
systemic amyloidosis, caused by a c.640G>A or c.640G>T (earlier known as G654A or
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G654T) gelsolin gene mutation. The disorder was originally identified in Finland in the late
1960s (Meretoja, 1969), but has since been reported from several countries in Europe, the
United States, Japan, Iran and Brazil (Kiuru-Enari &Haltia, 2013). The age of disease onset
is in the third or fourth decade of life. The three dominating clinical findings are corneal
lattice dystrophy, cutis laxa, and cranial neuropathy, but signs of CNS involvement have
also been observed, possibly related to gelsolin-related cerebral amyloid angiopathy (CAA)
(Kiuru et al., 1995; Kiuru, Salonen&Haltia, 1999).
CAA is characterized by progressive deposition of amyloid in cortical, subcortical and
leptomeningeal vessels, which can cause leucoencephalopathy, intracerebral hemorrhages
(ICH), cerebral microbleeds (CMB), ischemic infarcts, and dementia or cognitive dysfunc-
tion (Charidimou, Gang & Werring, 2012; Chao, Kotsenas & Broderick, 2006; Koennecke,
2006; Yamada, 2000). The diagnosis of CAA is neuropathologic, but the diagnosis can be
reached by brain imaging methods MRI and CT-data showing CAA-related pathology
particularly in the cortical-subcortical areas and in the white matter (Charidimou, Gang
& Werring, 2012; Chao, Kotsenas & Broderick, 2006; Koennecke, 2006). Several sporadic
and hereditary cerebrovascular amyloid proteins and types of CAA have been identified
(Charidimou, Gang & Werring, 2012; Yamada, 2000; Revesz et al., 2009). Genetic risk
factors for developing sporadic CAA are the apolipoprotein E (ApoE) alleles, which have an
important role in amyloid-beta metabolism, and are reported to influence an increased risk
for the CAA and CAA related ICH (Charidimou, Gang &Werring, 2012; Biffi et al., 2010).
Rare hereditary forms of CAA are based on mutations in the gene encoding the amyloid
precursor protein (APP), and the clinical manifestations differ from the sporadic type
of CAA (Charidimou, Gang &Werring, 2012; Haan et al., 1990). In gelsolin-related CAA
the amyloid distribution pattern has been distinct, predominant in smaller blood vessels
(Kiuru, Salonen & Haltia, 1999). The prevalence of sporadic CAA is reported to be higher
in the elderly population and it is strongly associated with Alzheimer’s disease (AD) (Ar-
vanitakis et al., 2011; Keage et al., 2009; Pfeifer et al., 2002; Farlow et al., 1992), but it is also
observed in elderly subjects without AD pathology (Arvanitakis et al., 2011; Soffer, 2006).
Through its association with vascular and white matter changes, it has been suggested
that CAA is an independent risk factor for clinically important cognitive dysfunction
(Greenberg et al., 2004). A study by Arvanitakis et al. (2011) (n = 404) showed that after
controlling for age, sex, education, AD-pathology, infarct and Lewy bodies, moderate-to
very severe CAA was associated with lower performance in perceptual speed and episodic
memory. Multiple cortical infarcts also had higher odds of dementia. No associations of
mild-to-moderate CAA with cognition were found. Cerebral microbleeds (CMB) have
been associated with deficits of executive functions independent of subtype of ischemic
stroke, white-matter lesions, hypertension and age (Werring et al., 2004). Vascular and
white matter pathology are known to be associated with impaired recall, processing speed
and executive functions, but also neuropsychiatric symptoms particularly depression
specifically in the elderly has been reported (Hommet et al., 2011). It has been suggested
that vascular pathology and white matter lesions may be associated with pathogenesis
of depression and depressive symptoms by disrupting the neural circuits between the
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frontal and subcortical regions (Naarding et al., 2005; Thomas et al., 2002). A previous
study of AGel amyloidosis with CNS involvement reported widespread spinal, cerebral
and meningeal amyloid angiopathy with deposition of AGel. A study by Kiuru, Salonen &
Haltia (1999) in four patients with a G654A gelsolin mutation revealed widespread areas
of diffuse signal increase in cerebral white matter, particularly in the frontal lobes and
the pons, in addition cerebral and a few cerebellar white-matter hypertensities were seen.
Histological findings revealed alterations of the white matter and involvement of spinal
and cerebral blood vessels and meninges, and slight to moderate diffuse loss of myelin
(Kiuru, Salonen & Haltia, 1999). Dementia is reported in single cases (Kiuru, Salonen
& Haltia, 1999; Darras et al., 1986; Haltia et al., 1991), potentially related to associated
CNS diseases. In the study of 31 AGel patients by Kiuru et al. (1995) minor signs of CNS
involvement were found in the MRI revealing significantly more frequent high intensity
lesions in subcortical and deep white matter, periventricular regions and/or in the pons.
Also, abnormal evoked potentials compared to the controls were reported. In the same
study the neuropsychological assessment in 30 AGel patients revealed subtle impairment
in abstract thinking, cognitive flexibility and visuoconstructional and -spatial difficulties,
suggesting CNS abnormalities, possibly with predominant frontal involvement. Depressive
symptoms were also reported.
The rationale behind searching neurocognitive changes in AGel amyloidosis stems from
two sources. Firstly, the CAA pathology is strongly associated with Alzheimer’s disease
(Arvanitakis et al., 2011; Keage et al., 2009; Pfeifer et al., 2002; Farlow et al., 1992), and
because of its association with vascular and white matter changes, CAA may be an
independent risk factor for cognitive dysfunction also in non-AD patients (Greenberg
et al., 2004). Therefore, the possibility of mild cognitive decline or dementia should be
investigated. Secondly, earlier studies have tentatively suggested signs of CNS involvement
especially in the fronto-subcortical regions in familial amyloidosis (Kiuru et al., 1995). The
prefrontal lobes give rise to three neuronal circuits affecting cognitive functions, behaviour
and mood; the dorsolateral prefrontal circuit mediates the organization of information to
facilitate a response; the anterior cingulate circuit is required for motivated behaviour, and
the orbitofrontal circuit is involved in the integration of limbic and emotional information
into behavioural responses (Cummings, 1990; Bonelli & Cummings, 2007). Impaired execu-
tive functions, apathy, and impulsivity are hallmarks of frontal-subcortical circuit dysfunc-
tion and therefore both neuropsychological and neuropsychiatric approach is warranted.
The aim of the present study is to investigate CNS abnormalities in AGel amyloidosis. A
group of AGel patients is assessed using neuropsychological, neuropsychiatric and neuro-
radiological methods and compared with healthy controls. Our hypothesis is that there are
subtle fronto-subcortical manifestations that affect cognitive and emotional performance.
METHODS
Participants
A total number of sixty-four (64) subjects, 35 AGel patients and 29 age-matched healthy
controls participated in the study. Four of the AGel patients were participants of an earlier
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Table 1 The demographic information of the AGel patient and the control group. The description of
number of cases, mean and standard deviation (SD) of age and education years.
AGel patients Controls
n= 35 n= 29
Female/male 23/12 18/11
Age 58.09 (10.41) 57.41 (11.07)
Range 31–74 32–77
Education 12.60 (2.47) 13.03 (2.73)
study by the same authors (Kiuru et al., 1995; Kiuru, Salonen & Haltia, 1999), others were
novel cases. There were no differences in age, education and gender between two subject
groups (Table 1).
The participants were recruited from the Department of Neurology in Helsinki Uni-
versity Central Hospital with patients’ age-matched healthy relatives with no amyloidosis
symptoms serving as a control group. Written informed consent was obtained from all
participants. This study was approved by the Ethics Committee for the Obstetrics and
Gynaecology, Paediatrics and Psychiatry, Hospital District of Helsinki and Uusimaa,
Finland, approval number HUS 213/E7/05.
The diagnosis of AGel amyloidosis was based on clinical examination, typical clinical
findings or demonstration of the G654A gelsolin gene mutation in patients (Paunio et
al., 1992). Detailed medical histories (neurologic and/or psychiatric diseases, diseases
predisposing to cerebrovascular disorders), use of CNS-affecting medication and alcohol
were obtained. The exclusion criteria were age under 18 years, pregnancy or other
diagnosed CNS-diseases.
Psychiatric assessment
All participants filled out the Beck Depression Inventory-II (BDI-II) (Beck, Steer & Brown,
1987; Beck, Steer & Brown, 2004), and the Symptom Check List-90 (SCL-90) (Derogatis,
Lipman & Covi, 1973; Holi, Sammallahti & Aalberg, 1998; Holi, Marttunen & Aalberg,
2003). The structured diagnostic psychiatric interview (Structured Clinical Interview for
DSM Disorders, SCID I and SCID II) (First et al., 1996; First et al., 1997) was used to
evaluate the current psychiatric diagnoses and psychiatric episodes in the past five years
of the patient and control participants. The structured interview was carried out without
blinding of the diagnostic group by psychiatrist Markku Kaipainen.
Neuropsychological assessment
A battery of selected neuropsychological tests was used to cover a wide range of basic and
higher-level cognitive functions. All assessments were carried out without blinding of the
diagnostic group by the first author MK in one session.
Verbal and non-verbal abstract thinking and strategic reasoning were measured by
four Wechsler Adult Intelligence test-Revised (WAIS-R) (Wechsler, 1981; Wechsler, 1992)
subtests Information, Similarities, Picture Completion and Block design. In the analyses
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we used the raw scores, age serving as a covariate. The WAIS-R Verbal Intelligence
Quotient (VIQ) was estimated using the Information and the Similarities subtests. The
Picture Completion and the Block design were used to estimate the WAIS-R Performance
Intelligence Quotient (PIQ).
To assess memory functions and learning we used the Logical Memory and the Visual
Reproduction subtests of the Wechsler Memory Scale-Revised (WMS-R) (Wechsler,
1987; Wechsler, 1996), and the Word list and the Letter-number Sequencing subtests of
the Wechsler Memory Scale-III (Wechsler, 1997; Wechsler, 2007). In the analysis we used the
raw scores, age serving as a covariate.
Attention, cognitive flexibility and processing efficacy we assessed with Trail Making
Test (TMT) parts A & B, the Stroop test (Stroop, 1935; Jensen & Rohwer, 1966), the Paced
Auditory Serial Addition Test (PASAT) (Gronwall, 1977), and the Digit symbol subtest
of the WAIS-R. In TMT the total test completion time and the number of errors were
measured in parts A and B separately (Lezak, Howieson & Loring, 2004). In addition, to
evaluate influence of speed in the test performance the difference score TMTb-TMTa was
calculated (Corrigan & Hinkeldey, 1987). In the Stroop test (100 items) we used the parts
Colour Naming (Part II) and Colour–Word Interference (Part III). In both parts, the total
test completion time, and the amount of errors and errors corrected were scored (Lezak,
Howieson & Loring, 2004). In addition, the total test completion time difference between
Parts II and III (Part II–Part II) was calculated (Lezak, Howieson & Loring, 2004; Corrigan
&Hinkeldey, 1987).
Visuoconstructional and visuospatial abilities were evaluated by paper- and pencil-
drawing tests (Lezak, Howieson & Loring, 2004; Christensen, 1974; Caplan & Romans, 1998)
and the CERAD Clock Drawing task (Consortium to Establish a Registry for Alzheimer’s
Disease) (Pulliainen et al., 1999; Sotaniemi et al., 2012). The test performance in the
visuoconstructional drawing task was scored from 1 to 3 (no abnormality, slight and
severe abnormality). In the CERAD Clock Drawing the overall shape, location of numbers,
clock hands and their direction are each scored yielding a total score ranking from 1 to 6.
Neuroradiological methods
Due to limited resources brain MRI was carried out to the first 16 patients (12 female
and 4 men, mean age 55.25 (SD = 9.89, range 38–74)) and the 14 first control subjects
(10 female and 4 men, mean age 57.07 (SD= 10.81, range 41–77)) recruited in the study.
Brain MRI was performed on 1.5 T machine (Siemens, Erlangen, Germany). All persons
had T2-weighted (axial and sagittal plane), fast-FLAIR and T2* (axial plane), T1-weighted
sagittal and DW-images. All brain abnormalities including infarcts and bleedings were
recorded without blinding of the diagnostic group by the author OS. The WMHIs were
classified as periventricular WMHIs or deep WMHIs and graded 0 through 3. The severity
of white matter lesions (WMLs) was rated with the Fazekas’ scale (Fazekas et al., 1987).
Statistical analysis
A multivariate analysis of covariance (MANCOVA) with age as a covariate was used
for the statistical analysis of differences in the psychiatric data of patient and control
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Table 2 The current psychiatric symptoms reported by the patient and the control group. The current
symptom means and standard deviations (SD) using the SCL-90 and BDI-II self-report inventories. Also,
statistical differences between the groups as well as the power of the analyses are presented.
AGel patients Controls p Adjusted p Partial η2 Power
Mean (SD) Mean (SD)
SCL-90 GSI* 1.66 (.47) 1.49 (.45) 0.17 0.56 .031 0.29
Somatic 2.09 (.65) 1.65 (.56) 0.006 0.03 .117 0.78
ocd 2.04 (.81) 1.88 (.78) 0.43 0.95 .010 0.12
Interpersonal 1.56 (.55) 1.51 (.57) 0.74 1.00 .002 0.06
Depression 1.83 (.73) 1.59 (.64) 0.19 0.60 .029 0.26
Anxiety 1.50 (.47) 1.37 (.44) 0.27 0.77 .020 0.19
Aggression 1.32 (.40) 1.33 (.39) 0.93 1.00 .000 0.05
Fobic 1.71 (.26) 1.14 (.28) 0.66 1.00 .003 1.00
Paranoia 1.34 (.42) 1.36 (.47) 0.86 1.00 .001 0.05
Psychotic 1.26 (.28) 1.22 (.29) 0.65 1.00 .003 0.08
Additional 1.99 (.68) 1.74 (.62) 0.13 0.46 .037 0.31
BDI-II total 7.46 (8.16) 3.79 (5.95) 0.048 0.21 .062 0.48
Notes.
* SCL-90 Global Severity Index.
groups using SPSS version 21 (IBM Corp., 2012). The subsequent univariate analyses were
carried out using the independent samples t-test or the analysis of covariance (ANCOVA)
adjusted for multiple comparisons using the Bootstrap method (R multtest package
(R Core Team, 2013; Pollard et al., 2013)). The neuropsychological tests were analysed
in three separate MANCOVA blocks: one for logical reasoning/intelligence measures,
one for memory measures and one for processing speed and accuracy measures. In
these multivariate analyses age was used as a covariate, and the subsequent univariate
analyses were carried out using the Bootstrap method. Power analysis for the differences
of means of the psychiatric and neuropsychological measures was carried out based
on the two samples’ t-tests (R pwr package). This was done without adjusting for age.
Additionally, a logistic regression analysis was conducted to examine the prediction of
group membership (AGel patients or controls) with the neuropsychological measured. To
avoid multicollinearity, only 13 neuropsychological variables with low inter-correlations
were chosen for the analysis. All predictor variables, along with age, were simultaneously
entered into the model. Chi-square-test was used for statistical analysis of discrete data,
such as the differences in the visuoconstructional performance. Unless otherwise stated,
all statistical comparisons are two-tailed. Descriptive statistics are given as means and
standard deviations (SD).
RESULTS
Neuropsychiatric findings
Table 2 shows the psychiatric symptomatology measured by SCL-90 and BDI-II self-report
inventories in the two groups. In an overall MANCOVA with all the subscales as well as the
BDI-II included and age used as a covariate, there was no significant effect of group (Wilks’
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Table 3 Logical reasoning and memory performance of the AGel patient and the control group. The mean and standard deviation (SD) of the
Wechsler Adult Intelligence Scale (WAIS-R) verbal and performance IQ, as well as the raw scores of the WAIS-R and Wechsler Memory Scale (WMS)
subtests. Also, statistical differences between the groups as well as the power of the analyses are presented.
AGel patients Controls p Adjusted p Partial η2 Power
Mean (SD) Mean (SD)
WAIS-R verbal IQ 115.11 (13.50) 112.90 (12.39) 0.52 0.94 .007 0.10
WAIS-R performance IQ 117.94 (12.71) 122.55 (14.02) 0.21 0.59 .025 0.26
WAIS-R information 25.49 (3.94) 24.59 (4.22) 0.39 0.85 .012 0.13
WAIS-R similarities 27.40 (3.48) 26.66 (3.62) 0.42 0.87 .011 0.13
WAIS-R picture completion 17.34 (1.96) 17.31 (2.71) 0.87 1.00 .000 0.05
WAIS-R block design 29.77 (9.06) 35.10 (8.24) 0.01 0.03 .104 0.64
WMS-R stories immediate recall 28.03 (5.74) 26.02 (7.05) 0.34 0.90 .015 0.23
WMS-R stories delayed recall 25.06 (6.27) 24.07 (7.75) 0.50 0.98 .007 0.08
WMS-R figures immediate recall 36.43 (4.46) 37.00 (3.95) 0.64 1.00 .004 0.08
WMS-R figures delayed recall 29.86 (9.98) 29.69 (11.45) 0.86 1.00 .000 0.05
WMS-III wordlist A total score 32.17 (5.79) 31.86 (6.77) 0.74 1.00 .002 0.05
WMS-III wordlist A interference 8.03 (2.12) 7.38 (2.91) 0.25 0.80 .021 0.17
WMS-III wordlist A delayed recall 7.17 (2.43) 7.00 (3.19) 0.71 1.00 .002 0.06
WMS-III letter-number sequencing 10.34 (2.95) 10.93 (2.87) 0.45 0.96 .009 0.12
Lambda= .755, F(12,50) = 1.35, partial η2 = .245) and the scores were relatively low in
both groups. Univariate comparisons revealed however that the somatic symptom subscale
of the SCL-90 was slightly more elevated in the patient group compared to the control
group (F(1,61)= 8.07, adjusted p= .03).
The results of the diagnostic psychiatric interview showed more lifetime clinical psychi-
atric disorders in the patient group. From the total of 35 patients, 10 had a clinically rele-
vant psychiatric disorder: nine had depression and one an anxiety disorder. In one case the
depression was diagnosed within one year before the AGel amyloidosis, in all other cases
the depression was in the temporal sense secondary to the AGel amyloidosis diagnosis. In
the control group (n= 29), one case of clinical depression and one of anxiety disorder was
found. The frequency of depression within the AGel patient group (26%) compared with
the control group (3%) was significantly higher (chi-square= 5.96, p= 0.015).
Neuropsychological findings
Table 3 shows the logical reasoning and the memory measures in the patient and the
control groups. Results were at an average or above average level on both groups. In MAN-
COVA, with age used as a covariate, no significant effect of group was found in the verbal
(VIQ) or the performance intelligence (PIQ) or in the subtests of the WAIS-R (Wilks’
Lambda= .828, F(6,56)= 1,94, partial η2 = .172). However, in subsequent analyses there
was a difference between the groups in the WAIS-R block design-subtest, the patient group
performing worse than the control group (F(1,61)= 7,12; adjusted p= .032).
The performance in verbal and visual memory and learning were at an average level in
both groups. In the MANCOVA with all the memory subscales, and age used as a covariate,
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Table 4 Processing speed and accuracy in the AGel patient and the control groups. The means and standard deviations (SD) in the tests of
processing speed and accuracy in the two groups. Also, statistical differences between the groups as well as the power of the analyses are presented.
AGel patients Controls p Adjusted p partial η2 Power
Mean (SD) Mean (SD)
TMA* 48.17 (19.16) 48.17 (15.57) 0.88 1.00 .000 0.05
TMB* 112.69 (48.45) 110.55 (50.79) 0.99 1.00 .000 0.05
TMB–A* 64.51 (35.65) 62.38 (45.80) 0.93 1.00 .000 0.06
Stroop II (colour naming)* 80.43 (15.38) 85.10 (18.43) 0.23 0.83 .024 0.19
Stroop III (colour-word interference)* 122.34 (21.09) 139.97 (34.13) 0.01 0.09 .102 0.68
Stroop III–II 41.91 (14.51) 54.86 (25.63) 0.01 0.11 .096 0.69
PASAT correct 41.83 (13.51) 42.97 (10.15) 0.76 1.00 .001 0.07
PASAT errors 5.34 (3.72) 3.76 (2.69) 0.06 0.29 .057 0.44
WAIS-R digit symbol 42.49 (13.01) 44.93 (10.59) 0.58 0.96 .005 0.12
Errors (TM and Stroop) total 6.77 (4.53) 4.72 (3.28) 0.04 0.21 .067 0.49
Notes.
* Seconds.
no significant effect of group was found (Wilks’ Lambda= .919, F(8,54) = .594, partial
η2 = .081) and the subsequent univariate analyses revealed no further differences. There
were no statistical differences in immediate or delayed memory or learning between the
patient and control groups.
No significant difference in the processing speed between the groups was found. In
the MANCOVA with all the tests of executive functions and attention, and age used as a
covariate, there was no significant effect of group (Wilks’ Lambda= .809, F(8,54)= 1,59,
partial η2 = .191). In univariate comparisons there was an indication of faster performance
of the AGel group in the Stroop Colour–Word Interference test and in the Stroop III–II
time difference, but these differences were not significant after adjusting for multiple
comparisons (see Table 4). Additionally, there were some indications of differences
between the groups in processing efficacy and accuracy. Univariate comparisons revealed
that the sum of errors in all these tests was slightly elevated in the patient group compared
to the control group, but the difference was not statistically significant.
The logistic regression analysis with 13 neuropsychological variables revealed a
significant model with 83% of all cases correctly classified (chi-square= 32.2, p = 0.004).
Two predictors were significant: WAIS-R Block design and total sum of errors in TM and
Stroop (see Table 5).
There were differences in visuoconstructional abilities in the drawing tasks, showing
more errors or difficulties in the patient group (chi-square= 7.96, p = .014) using exact
test (Table 6, see also Supplemental Information S1). In the clock-drawing task there was
no significant difference in the performance of the patient and the control group; the mean
score of the patient group was 5.37 (SD 0.91) and the controls 5.52 (SD 0.63).
Neuroradiological findings
Four of the 16 patients had either single microhemorrhage or microcalcification on the
MRI while none of the 14 control subjects had them (chi-square = 4.04, one-tailed
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Table 5 Logistic regression analysis for the prediction of group membership (AGel patients or controls).
Odds ratios (OR) as well as 95% confidence intervals (CI) for the OR are given.
B S.E. OR 95% CI Wald p
Lower Upper
Constant −0.75 7.00 0.01 0.91
Age 0.07 0.05 1.07 0.96 1.19 1.51 0.22
WAIS-R information −0.17 0.13 0.84 0.65 1.10 1.61 0.21
WAIS-R similarities 0.05 0.14 1.05 0.79 1.38 0.10 0.75
WAIS-R picture completion −0.23 0.21 0.80 0.53 1.19 1.23 0.27
WAIS-R block design 0.27 0.08 1.31 1.12 1.54 11.03 0.001
WMS-R stories immediate recall −0.05 0.08 0.95 0.81 1.11 0.41 0.52
WMS-III letter-number sequencing 0.25 0.18 1.29 0.91 1.82 2.02 0.15
WMS-R figures immediate recall −0.17 0.14 0.85 0.64 1.12 1.39 0.24
WMS-R figures delayed recall −0.09 0.05 0.92 0.84 1.01 3.14 0.08
WMS-III wordlist A total score 0.01 0.09 1.01 0.85 1.21 0.02 0.90
TMB* 0.01 0.01 1.01 0.99 1.04 0.68 0.41
PASAT correct 0.00 0.04 1.00 0.92 1.09 0.00 0.99
Stroop III (colour-word interference)* 0.02 0.02 1.02 0.99 1.05 1.87 0.17
Errors (TM and Stroop) total −0.34 0.14 0.71 0.55 0.93 6.24 0.01
Notes.
* Seconds.
Table 6 Visuoconstructional copying in the AGel patients and the control group. The qualitative
scoring and the differences in the visuoconstructional copying task between the AGel patients and the
control group. See also Supplemental Information S1.
AGel patients
(n= 35)
Controls
(n= 29)
No abnormality (n) 11 18
Slight abnormality (n) 22 8
Severe abnormality (n) 2 3
p < .022). One patient had multiple hemorrhages, and one patient had a sign of a small
old infarct. No significant differences in WMHI or atrophy ratings were found between
patients and age-matched control subjects. The neuropsychological test results and the
psychiatric status of the AGel patients with microhemorrhages are shown in Table 7. There
was no clear association between microhemorrhages/microcalcifications and specific
neuropsychological or neuropsychiatric symptoms on the group level. However, when
the raw scores are compared with the scores of the control group (Tables 3 and 4) it can
be seen that patient A had some difficulty in delayed verbal memory (WMS-R stories
and WMS-III wordlist) as well as in processing accuracy and speed (TM and Stroop),
patient C in processing accuracy (PASAT and errors total) and patient D in visual delayed
memory (WMS-R figures) and attention (WMS-III letter-number sequencing, WAIS
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Table 7 The neuropsychological test results and the psychiatric status of the four AGel patients with
microhemorrhages in the MRI.
Patient A Patient B Patient C Patient D
Sex (female/male) F F F M
Age (years) 60 68 59 59
BDI-II 10 11 9 9
Psychiatric diagnosis No No Depression Anxiety
WAIS-R verbal IQ 96 133 120 99
WAIS-R performance IQ 120 116 127 130
WMS-R stories immediate recall 25 26 26 30
WMS-R stories delayed recall 19 25 22 25
WMS-R figures immediate recall 34 38 39 38
WMS-R figures delayed recall 31 38 32 21
WMS-III wordlist A total score 29 27 33 28
WMS-III wordlist A interference 5 9 10 6
WMS-III wordlist A delayed recall 4 6 8 7
WMS-III letter-number sequencing 7 10 11 2
Visuoconstructional drawings (1–3) 2 2 2 2
Clock drawing (0–6) 5 5 5 6
TMA 48 64 78 42
TMB 175 126 142 98
TMB–A 127 62 64 56
Stroop part II (colour naming) 92 94 76 85
Stroop part III (colour-word interference) 159 110 119 137
Stroop Part III–II 67 16 43 52
PASAT correct 31 52 38 –
PASAT errors 3 8 11 –
WAIS-R digit symbol 34 40 35 29
Errors total 6 8 11 12
digit symbol and errors total). Patients C and D also had clinically relevant psychiatric
disorder, depression and anxiety, and all patients (A to D) reported more depression
related symptoms compared with controls (see Table 2). Patient A had been diagnosed with
hypertension two years prior to the AGel amyloidosis diagnosis. Patients B, C and D had no
cerebrovascular predisposing factors in their medical histories.
DISCUSSION
In the present study we examined the possible CNS involvement in AGel amyloidosis using
a controlled study design. Our aim was to pay special attention to findings associated
with the disruption of the fronto-subcortical circuits. The present data show subtle
indication of neuropsychiatric, neurocognitive and MRI findings associated with AGel
amyloidosis supporting our hypothesis. The patient group reported more depression and
somatic symptoms than the control group and showed more clinically relevant psychiatric
disorders, mainly depression. In neuropsychological testing, we found some indication
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of problems in processing efficacy and accuracy, and more clearly in visuoconstructional
or visuospatial abnormality in AGel group. On the MRI, the findings were elevated in the
patient group, showing either microhemorrhages or microcalcifications.
There were minor differences in the current psychiatric symptomatology between
the groups in self-report measures, patients reporting more somatic symptoms than
the controls. There was no clear difference in the current self-reported symptoms of
depression. In clinical psychiatric evaluation assessing both past and present situation
however the patient group showed clinically relevant psychiatric disorders, mainly
depression, more frequently. The depression-related symptomatology may partly be
reactive to the AGel disease and its effects to functional ability and quality of life. The
somatic symptoms reported by the patients, such as reduced sleep or lack of energy, may
be associated with the clinical manifestations of the AGel amyloidosis or they can reflect
the somatic component of depression. Since vascular and white matter pathology are
associated with pathogenesis of depression and depressive symptoms (Naarding et al.,
2005), our findings raise the question of possible organic pathology behind the depressive
symptomatology found mainly in the patient group.
In the neuropsychological assessment no differences between the patient and the
control group were found in the verbal or the performance intelligence or memory
functions. Even in the individual cases with neuroradiological findings, the cognitive
profile remained well preserved, and there was no sign of rapid forgetting (immediate vs.
delayed memory scores compared), one of the hallmarks of Alzheimers’ disease. It can be
concluded that in this form of AGel amyloidosis, dementia does not appear to be prevalent.
Similar was the finding also in the previous study of 31 cases (Kiuru et al., 1995), although
dementia has been reported in single patients (Kiuru, Salonen &Haltia, 1999; Darras et al.,
1986; Haltia et al., 1991).
Subtle differences in the neuropsychological performance were discovered however. The
visuoconstructional difficulties of the patient group were evident both in the block design
test and in the drawing task. The overall processing speed was equal in both groups, but the
patient group showed a tendency towards more errors in their responses. The patients were
currently no more depressed than the controls so that did not explain the findings. In fact,
the control group was slower in the Stroop test, and it appears that the AGel patients traded
accuracy for speed and failed to control for errors. The processing and response accuracy
may reflect problems in action control and executive functions. Also, in addition to visual
processing, the constructional performance is strongly associated with executive functions
such as planning, organization of action and cognitive flexibility, all requiring frontal
involvement. Difficulties in processing accuracy, action control and visuoconstructional
performance may be an indicator of organic pathological changes in frontal or fronto-
subcortical circuits. In previous studies on CAA, cerebral microbleeds and cognition, lower
perceptual or processing speed, problems in executive functions, poor episodic memory
and impaired recall have been the main neuropsychological findings reported (Arvanitakis
et al., 2011; Greenberg et al., 2004; Poels et al., 2012; Gregoire et al., 2012).
Kantanen et al. (2014), PeerJ, DOI 10.7717/peerj.493 11/16
Microhemorrhages are considered to be associated with cerebral small vessel
pathologies and CAA. In our study the MRI showed differences between the groups as
microhemorrhages and microcalcifications were mainly found in the AGel patient group.
There were no significant differences in WMHI or atrophy ratings between patients and
control subjects. The group was also too small for any clear associations to emerge between
microhemorrhages or microcalcifications and specific neuropsychological or psychiatric
symptoms. The four individual AGel patients with MRI-findings showed mild cognitive
problems in processing and memory functions as well as psychiatric symptomatology but
this finding should be viewed with caution due to the qualitative nature of the case analysis.
It has been suggested that CAA and its clinical manifestations are more common in the
elderly population. In our study we examined participants with a mean age under 60 and
it is possible that the changes we found on the MRI and in the neurocognitive functions
could be more evident in more elderly study subjects.
Our study has two notable limitations. The sample size is relatively small and therefore
the statistical power in the analyses remained low. Possibly with larger samples more
differences would have emerged. AGel amyloidosis however is an uncommon disease and
collection of large study groups in a low population country is very time consuming.
We believe that by reporting these findings we can enhance more international research
in the area. The second limitation is the un-blinded method of data collection. It can
be hypothesized that the knowledge of the group membership can affect the overall
impression of the rater resulting in exaggeration of the negative findings in patients. As
AGel amyloidosis is a disease often resulting in noticeable changes in the skin tissue (cutis
laxa), particularly in the facial area, blind evaluation is difficult to accomplish. Relying on
global impressions or interview data alone is therefore unadvisable. Objective measures
should always be included, as was done in our study.
In conclusion, previous studies have suggested minor CNS abnormalities in AGel
amyloidosis, possibly related to cerebral amyloid angiopathy (CAA). Our findings
conducted in a controlled study design confirm this and indicate subtle changes in
the MRI, neurocognitive function and psychiatric symptomatology in the AGel group
compared to age-matched control subjects. Longitudinal studies are needed to investigate
whether these findings are progressing in the course of the illness.
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